Jiangsu Hengrui Pharma Receives FDA Warning Letter
Hengrui Pharma`s Generic Bupivacaine liposome Receives Approval in US
Employees of Chinese drugmaker Jiangsu Hengrui Pharmaceuticals “diverted” FDA inspectors as colleagues tore up and threw away documents in a “rapid-like manner” at a manufacturing …
FDA Issues Form 483 to Jiangsu Hengrui Pharmceuticals
FDA rejects Elevar, Hengrui`s PD-1 combo
Investors put $400M into biotech licensing obesity drugs from China
PRINCETON, N.J. and FORT LEE, N.J. Oct. 17, 2023 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma), one of China™s largest pharmaceutical companies based on market...
Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progression-Free Survival vs Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in a Multinational Phase 3 Trial, a Joint Program with Elevar Therapeutics
PARIS, Sept. 10, 2022 /PRNewswire/ -- Jiangsu Hengrui Pharmaceuticals Co., Ltd., one of the largest biopharmaceutical companies headquartered in China, today announced top-line results from the phase 3 study of camrelizumab (anti-PD1 checkpoint inhibitor) combined with rivoceranib (apatinib) vs. sorafenib as a first-line therapy for uHCC. Camrelizumab plus rivoceranib significantly prolonged overall survival (OS) and progression-free survival (PFS), and improved overall response rate (ORR) vs. sorafenib, a standard first-line treatment for uHCC.